Five cases of uterine perivascular epithelioid cell tumors (PEComas) and review of literature
- 193 Downloads
Perivascular epithelioid cell tumor (PEComa) is a rare condition and the recognition of this condition is limited. Here we report five cases of uterine PEComa to add to the limited understanding of this rare condition.
Five cases from Obstetrics and Gynecology Hospital of Fudan University were diagnosed as uterine PEComas. We collected the patients’ clinical and pathological data as well as their outcomes.
All the five cases were diagnosed post-operationally. Fertility-sparing surgery was done for the first case and had a mass resection only. She delivered a healthy boy through the cesarean section in November 2016 and neither recurrence nor metastasis was found for 71 months. Hysterectomy was done for the other four cases. Adjuvant chemotherapy was also given for case 2 and case 4. Case 2 had combined endometrial cancer, which could be associated with tuberous sclerosis complex (TSC). She was followed up for 22 months and neither recurrence nor metastasis was detected. Neither recurrence nor metastasis was found in case 3 for 33 months. However, the patient in case 4 died of multiple dissemination and multiple organs failures, 10 months after the second surgery. The patient in case 5 had the hysterectomy and left adnexal resection and in this case we had no data about her long-term outcomes.
It is still challenging to detect and diagnose uterine PEComa clinically and no consensus or guidelines have been established regarding the treatment of this condition. More case studies are needed to enlighten the underlying mechanism and help optimize the therapies for this condition.
KeywordsPEComa Uterus Case reports
WWS: manuscript writing/editing. XJC: supportive supervision. XZL: provided the source information and idea, manuscript editing, supervision. YS: language editing. QZ: pathology review. BYY, LYX, BL, CCN, QYLV, YLC, BYX, MZB, YHX: follow-up and searching medical records.
Compliance with ethical standards
Conflict of interest
All authors declare no conflict of interest.
This report complies with the tenets of the Declaration of Helsinki, and the medical ethics committee of the Obstetrics and Gynecology Hospital of Fudan University approved this study. Informed consent was obtained from all the five patients in this report.
- 5.Gao F, Huang C, Zhang Y, Sun R, Zhang Y, Wang H, Zhang S (2016) Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remarkable response of rapid progressive uterine PEComa. Cancer Biol Ther 17(6):595–598. https://doi.org/10.1080/15384047.2016.1167290 CrossRefGoogle Scholar
- 7.Schoolmeester JK, Dao LN, Sukov WR, Wang L, Park KJ, Murali R, Soslow RA (2015) TFE3 translocation-associated perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: morphology, immunophenotype, differential diagnosis. Am J Surg Pathol 39(3):394–404. https://doi.org/10.1097/PAS.0000000000000349 CrossRefGoogle Scholar
- 8.Schoolmeester JK, Howitt BE, Hirsch MS, Dal Cin P, Quade BJ, Nucci MR (2014) Perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: clinicopathologic and immunohistochemical characterization of 16 cases. Am J Surg Pathol 38(2):176–188. https://doi.org/10.1097/PAS.0000000000000133 CrossRefGoogle Scholar
- 9.Starbuck KD, Drake RD, Budd GT, Rose PG (2016) Treatment of advanced malignant uterine perivascular epithelioid cell tumor with mTOR inhibitors: single-institution experience and review of the literature. Anticancer Res 36(11):6161–6164. https://doi.org/10.21873/anticanres.11208 CrossRefGoogle Scholar